Enanta Pharmaceuticals, Inc. Announces The Initiation Of Phase 2b Clinical Trial With Regimen Containing HCV Protease Inhibitor ABT-493

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie, Enanta’s development partner for protease inhibitors for hepatitis C virus (HCV), has initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration.

The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530, AbbVie’s next generation NS5A inhibitor, in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year. Additional details regarding this study will be available when they are posted by AbbVie at www.clinicaltrials.gov.

Help employers find you! Check out all the jobs and post your resume.